Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is underpriced on P/E, overvalued on P/FC.
Target Price
The average target price of 1167.HK is 5.3 and suggests 10% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to d
Buy
Sell